Urothelial Carcinoma Treatment Global Market Report 2025
상품코드:1825575
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
요로상피암 치료 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 연평균 성장률(CAGR) 16.7%로 62억 3,000만 달러로 성장합니다. 예측 기간의 성장은 인구 고령화, 맞춤형 의료에 대한 수요, 요로상피암 연구 및 치료에 대한 정부 지원 증가, 요로상피암 치료에 대한 투자 증가에 기인합니다. 예측 기간의 주요 동향으로는 바이오마커 기반 치료, 신 보조제 및 보조제 접근법, 액체생검, 최소침습 수술, 화학요법 개발, 디지털 헬스 기술 등이 있습니다.
향후 5년간 16.7%의 성장률 전망은 지난번 예측보다 0.1% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 장벽은 스위스나 영국에서 조달하는 면역치료제나 방광경 검사 장비의 비용을 상승시켜 암 치료를 지연시키거나 종양학 지출을 증가시킴으로써 미국을 저해할 것으로 예측됩니다. 또한 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.
방광암 발병률 증가는 향후 요로상피암 치료제 시장 확대를 견인할 것으로 예측됩니다. 방광암은 방광을 감싸고 있는 세포를 침범하는 흔한 암으로, 환자와 의료진에게 다양한 치료 옵션이 필요한 질환입니다. 방광암에 대한 연구는 표적치료에 대한 정보를 제공하고, 요로상피암에 대한 이해를 높이고, 치료 결과를 개선하기 위한 다학제적 접근을 촉진하는 데 도움이 될 것입니다. 예를 들어 2023년 9월 미국 연방정부가 운영하는 의학도서관인 국립의학도서관은 2040년까지 신규 방광암(BCa) 환자 수가 2020년 대비 72.8% 증가한 99만 1,000명에 달할 것으로 예측했습니다. 또한 BCa와 관련된 연간 사망자 수는 39만 7,000명에 달하고, 86.6% 증가할 것으로 예측됩니다. 그 결과, 방광암 발병률 증가는 요로상피암 치료제 시장을 촉진할 것으로 보입니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 요로상피암 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 요로상피암 치료 시장 : 성장률 분석
세계의 요로상피암 치료 시장 실적 : 규모와 성장, 2019-2024
세계의 요로상피암 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 요로상피암 치료 : TAM(Total Addressable Market)
제6장 시장 세분화
세계의 요로상피암 치료 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
비침습적 요로상피암 치료
침습적 요로상피암 치료
세계의 요로상피암 치료 시장 치료별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
면역치료
방사선 요법
화학요법
세계의 요로상피암 치료 시장 암 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
방광암
요도암
요관암 및 신우암
세계의 요로상피암 치료 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
홈케어
전문 센터
기타 최종사용자
세계의 요로상피암 치료 시장 : 서브 세분화 비침습성 요로상피암 치료(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
방광내 요법
면역치료
화학요법
세계의 요로상피암 치료 시장 : 서브 세분화 침습성 요로상피암 치료(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
근치적 방광 적출술
화학요법
방사선 치료
표적치료
제7장 지역별·국가별 분석
세계의 요로상피암 치료 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 요로상피암 치료 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
요로상피암 치료 시장 : 경쟁 구도
요로상피암 치료 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
Bayer AG
Sanofi S.A.
Bristol-Myers Squibb Company
AstraZeneca PLC
Abbott Laboratories Inc.
GlaxoSmithKline PLC
Astellas Pharma Inc.
Agilent Technologies Inc.
Eisai Co. Ltd
Incyte Corporation
Hikma Pharmaceuticals PLC
Amneal Pharmaceuticals LLC
Seagen Inc.
Lupin Limited
Genentech Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
요로상피암 치료 시장 2029 : 새로운 기회를 제공하는 국가
요로상피암 치료 시장 2029 : 새로운 기회를 제공하는 부문
요로상피암 치료 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁사 전략
제36장 부록
KSA
영문 목차
영문목차
Urothelial carcinoma is a form of cancer that originates in the urothelial cells lining the interior of the urinary system, encompassing the bladder, ureters (connecting tubes between the kidneys and the bladder), and the renal pelvis (the kidney segment responsible for collecting urine). Treatments for urothelial carcinoma, involving both surgical procedures and intravenous therapies, play a crucial role in managing the disease, enhancing patient outcomes, and improving their quality of life.
The primary categories of urothelial carcinoma treatment are non-invasive and invasive. Non-invasive treatment pertains to addressing early-stage bladder cancer that has not spread to the deeper layers of the bladder or surrounding tissues. This is achieved through techniques like transurethral resection of bladder tumors (TURBT), which entails the removal of cancerous tissue from the bladder lining, and intravesical therapies, where medications are directly delivered into the bladder to prevent recurrence. These treatments, encompassing immunotherapy, radiotherapy, and chemotherapy, are also employed to address various types of urinary system cancers, including bladder, urethral, ureteric, and renal pelvic cancers. These treatments serve a variety of end users, including hospitals, homecare services, specialty centers, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The urothelial carcinoma treatment market research report is one of a series of new reports from The Business Research Company that provides urothelial carcinoma treatment market statistics, including urothelial carcinoma treatment industry global market size, regional shares, competitors with a urothelial carcinoma treatment market share, detailed urothelial carcinoma treatment market segments, market trends and opportunities and any further data you may need to thrive in the urothelial carcinoma treatment industry. This urothelial carcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The urothelial carcinoma treatment market size has grown rapidly in recent years. It will grow from $2.86 billion in 2024 to $3.36 billion in 2025 at a compound annual growth rate (CAGR) of 17.6%. The growth in the historic period can be attributed to rising prevalence of urothelial carcinoma, growing awareness of urothelial carcinoma, increasing access to healthcare, rising disposable incomes.
The urothelial carcinoma treatment market size is expected to see rapid growth in the next few years. It will grow to $6.23 billion in 2029 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to aging population, demand for personalized medicine, rising government support for urothelial carcinoma research and treatment, growing investments on urothelial carcinoma treatment. Major trends in the forecast period include biomarker-driven therapies, neoadjuvant and adjuvant approaches, liquid biopsies, minimally invasive surgeries, chemotherapy development, digital health technologies.
The forecast of 16.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. by increasing the cost of immunotherapy drugs and cystoscopy equipment sourced from Switzerland and the UK, thereby delaying cancer interventions and elevating oncology department expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The growing incidence of bladder cancer is expected to drive the expansion of the urothelial carcinoma treatment market in the future. Bladder cancer is a common cancer that affects the cells lining the urinary bladder, leading to the need for a variety of treatment options for patients and healthcare providers. Research into bladder cancer helps inform targeted therapies and enhances understanding of urothelial carcinoma, promoting cross-disciplinary approaches to improve treatment outcomes. For example, in September 2023, the National Library of Medicine, a U.S.-based medical library operated by the federal government, projected that the number of new bladder cancer (BCa) cases would reach 991,000 by 2040, reflecting a 72.8% increase from 2020. Annual BCa-related deaths are also expected to rise to 397,000, marking an 86.6% increase. As a result, the growing incidence of bladder cancer will drive the urothelial carcinoma treatment market.
The growing demand for chemotherapy is anticipated to be a significant driver for the growth of the urothelial carcinoma treatment market in the foreseeable future. Chemotherapy is a medical treatment that employs drugs to target and eradicate rapidly dividing cells within the body, commonly employed in cancer treatment. Chemotherapy's pivotal role stems from its effectiveness in managing various stages of the disease, making it an integral approach in urothelial carcinoma treatment. For instance, as of June 2023, Mesothelioma.com, a medical information provider based in the United States, reports that approximately 25% of cancer patients in the US receive chemotherapy each year. Hence, the increasing demand for chemotherapy is set to propel the urothelial carcinoma treatment market.
The prominent companies operating in the urothelial carcinoma treatment market are actively dedicated to introducing innovative products to enhance their competitive positions and meet the changing needs of their customers. For example, in March 2023, Nonacus Limited, a UK-based medical product manufacturer, unveiled GALEAS Bladder, a cutting-edge diagnostic test designed for the non-invasive detection of bladder cancer. GALEAS Bladder represents a significant advancement in bladder cancer diagnostics, offering a comprehensive molecular triage solution that seamlessly moves from sample collection to the final diagnostic report. It leverages a molecular biomarker with exceptional sensitivity to quickly and accurately identify bladder cancer, simplifying the diagnostic process and reducing the necessity for invasive procedures like cystoscopies. Developed in partnership with the University of Birmingham in the UK, GALEAS Bladder has undergone rigorous validation, involving over 600 patient samples from three distinct clinical cohorts in the UK. This extensive assessment underscores the remarkable performance of GALEAS Bladder, delivering high diagnostic accuracy (with a sensitivity exceeding 90% and specificity over 85%) and effectively catering to varying bladder cancer grades and stages.
In September 2024, A. Menarini Diagnostics, an Italy-based pharmaceutical company, entered into a partnership with Nucleix to enhance product marketing. As part of this collaboration, A. Menarini Diagnostics will assume exclusive marketing rights for the non-invasive Bladder EpiCheck test across Europe in the coming months. This urine test will provide patients and clinicians with an effective tool for detecting and monitoring the recurrence of bladder cancer and upper tract urothelial carcinoma (UTUC). Nucleix, an Israel-based company, specializes in the development and sale of non-invasive cancer tests.
North America was the largest region in the urothelial carcinoma treatment market in 2024. The regions covered in urothelial carcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the urothelial carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The urothelial carcinoma treatment market consists of revenues earned by entities by providing transurethral resection (TURBT) surgery and external beam radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The urothelial carcinoma treatment market also includes sales of platinum-based chemotherapy drugs such as cisplatin or carboplatin and immune checkpoint inhibitor drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Urothelial Carcinoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on urothelial carcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for urothelial carcinoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The urothelial carcinoma treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
3. Urothelial Carcinoma Treatment Market Trends And Strategies
4. Urothelial Carcinoma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Urothelial Carcinoma Treatment Growth Analysis And Strategic Analysis Framework
5.1. Global Urothelial Carcinoma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Urothelial Carcinoma Treatment Market Growth Rate Analysis
5.4. Global Urothelial Carcinoma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Urothelial Carcinoma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Urothelial Carcinoma Treatment Total Addressable Market (TAM)
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Urothelial Carcinoma Treatment Market
9.1. China Urothelial Carcinoma Treatment Market Overview
9.2. China Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Urothelial Carcinoma Treatment Market
10.1. India Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Urothelial Carcinoma Treatment Market
11.1. Japan Urothelial Carcinoma Treatment Market Overview
11.2. Japan Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Urothelial Carcinoma Treatment Market
12.1. Australia Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Urothelial Carcinoma Treatment Market
13.1. Indonesia Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Urothelial Carcinoma Treatment Market
14.1. South Korea Urothelial Carcinoma Treatment Market Overview
14.2. South Korea Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Urothelial Carcinoma Treatment Market
15.1. Western Europe Urothelial Carcinoma Treatment Market Overview
15.2. Western Europe Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Urothelial Carcinoma Treatment Market
16.1. UK Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Urothelial Carcinoma Treatment Market
17.1. Germany Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Urothelial Carcinoma Treatment Market
18.1. France Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Urothelial Carcinoma Treatment Market
19.1. Italy Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Urothelial Carcinoma Treatment Market
20.1. Spain Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Urothelial Carcinoma Treatment Market
21.1. Eastern Europe Urothelial Carcinoma Treatment Market Overview
21.2. Eastern Europe Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Urothelial Carcinoma Treatment Market
22.1. Russia Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Urothelial Carcinoma Treatment Market
23.1. North America Urothelial Carcinoma Treatment Market Overview
23.2. North America Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Urothelial Carcinoma Treatment Market
24.1. USA Urothelial Carcinoma Treatment Market Overview
24.2. USA Urothelial Carcinoma Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Urothelial Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Urothelial Carcinoma Treatment Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
